[go: up one dir, main page]

EP1086130A1 - Analogue de l'insuline - Google Patents

Analogue de l'insuline

Info

Publication number
EP1086130A1
EP1086130A1 EP98928469A EP98928469A EP1086130A1 EP 1086130 A1 EP1086130 A1 EP 1086130A1 EP 98928469 A EP98928469 A EP 98928469A EP 98928469 A EP98928469 A EP 98928469A EP 1086130 A1 EP1086130 A1 EP 1086130A1
Authority
EP
European Patent Office
Prior art keywords
insulin
ins
binding
compound according
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98928469A
Other languages
German (de)
English (en)
Inventor
Richard Henry Jones
Dietrich Brandenburg
Fariba Shojaee-Moradi
Jens Kleinjung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
Deutsches Wollforschungsinstitut
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Wollforschungsinstitut, Kings College London filed Critical Deutsches Wollforschungsinstitut
Publication of EP1086130A1 publication Critical patent/EP1086130A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel insulin analogues which are covalent conjugates of an insulin molecule and a derivative of the hormone thyroxine, 3,3' ,5' triiodothyronine .
  • T4 thyroxine binding proteins
  • T4-insulin conjugate may retain thyroxine activity.
  • the present invention seeks to solve this problem while providing a conjugate which retains its hepatoselectivity, insulin activity and circulating protein affinity.
  • a new compound according to the invention comprises an insulin molecule covalently bound to 3,3',5'- triiodothyronine .
  • the 3 , 3 ' , 5 ' triiodothyronine molecule is not a naturally occurring compound. It is an isomer of 3,5,3' triiodothyronine (T3) and is consequently known as reverse T3 , rT3. It has insignificant activity on thyroxine receptor, but thyroxine binding proteins have an affinity for the molecule. Thus the compound of the invention should have affinity for TBP's and, it is believed, consequential hepatoselectivity whilst the compound and its metabolites should not stimulate thyroxine activity.
  • the rT3 moiety should be conjugated to a residue of the insulin molecule such that insulin activity is not adversely affected. As in O-A-95/05187, conjugation is preferably through the Bl residue of insulin. Alternatively the B29 residue may be linked to rT3. In O- 95/07931, the B29 residue may be derivatised and the methods of conjugating a carboxylic acid-containing compound to the B29 residue as disclosed in that reference may be used in the present invention.
  • the insulin may be made by recombinant DNA techniques or may be isolated from natural sources, human or animal. Recombinant insulin may have deleted residues as desired, for instance the B29 residue may be deleted. Other residues of naturally occurring insulin may be substituted, usually by conservative substitutions. For instance in WO- A-95/07931, analogues in which the B3 and/or A21 residues are other than those of naturally occurring insulin.
  • the rT3 molecule is conjugated to the insulin using conventional biochemical techniques in which pendant groups on the appropriate residue of the insulin molecule are covalently bonded to rT3 , through the carboxylate group. The pendant group is usually the e-amino group of a lysine residue. Any other lysine residues may be rendered unreactive by protecting the e-amine groups using conventional techniques. Protecting groups are removed after conjugation to the rT3 molecule.
  • the phenolic OH group of rT3 is protected during the process, also. Either or both of the amine group and the carboxylate group may be activated prior to contact of the insulin with the rT3. Conventional techniques for generation of amide linkages may be used, for instance using known reagents.
  • a spacer may be included between the insulin molecule and the rT3 molecule.
  • a spacer may, for instance, improve retention of insulin activity and/or TBP-binding.
  • a spacer may also be used to control in vivo cleavage and metabolism of the conjugate compound, and consequently its insulin activity.
  • a spacer may, for instance include a chain comprising 2 to 22 carbon and/or heteroatoms, such as a 4- 10 atom chain, preferably comprising an alkylene group and carbonyl and/or amino groups, amido groups and or oxygen atoms in ester or ether linkages.
  • the insulin-rT3 conjugate has a similar potency relative to human insulin itself. This is in contrast to T4-insulin, which appears to have a greater potency than human insulin. In the presence of binding proteins, especially thyroxin binding proteins, the potency of T4-insulin is reduced, whereas these proteins do not affect the potency of rT3 -insulin. These data indicate that the conjugate is likely to have similar effects as insulin in vivo .
  • the novel compound is suitable for use in a method of treatment of the human or animal , for instance to replace insulin in a method of insulin replacement therapy.
  • the invention thus comprehends novel compositions containing the compound as well as pharmaceutical compositions containing the compound and a pharmaceutically acceptable excipient .
  • the composition is formulated so as to be suitable for administration by the usual routes, generally by subcutaneous injection. Accordingly the carrier is generally aqueous.
  • the invention comprehends also a new use of the compound in the manufacture of a medicament for use in a method of treatment of the human or animal body.
  • the protein material was diluted in a mixture of 1 ml dimethylformamide, 1.5 ml methanol and 1.5 ml water. The solution was cooled to 0°C and addition of 0.5 ml of ice-cold 2 M sodium hydroxide solution started the cleavage reaction. The reaction was stopped by acidification with 1 ml of 10% (v/v) acetic acid. The protein was precipitated by pipetting the reaction solution into a mixture of 250 ml of ice-cold ether and 20 ml methanol and stirring for 1 h. The ether was decantated from the precipitated protein and the protein dried in vacuo .
  • the rT3 -insulin conjugate made in Example 1 is used in various tests to determine the binding potencies of the analogues on liver plasma membrane.
  • 125 -Insulin is used as the labelled insulin. It is known that insulin itself inhibits binding of 125 -Insulin.
  • THBP does not appear to affect the ability of H-Ins to inhibit the binding of 125 -Insulin to insulin receptors on LPM.
  • THBP does not appear to affect the ability of rT3-Ins to inhibit the binding of 125 -Insulin to insulin receptors on LPM.
  • TBG seems to have the greatest effect on T4-Ins, i.e. causes the greatest shift.
  • the ED50's as calculated by the G-PIP software were inverse logged because the concentrations entered in G-PIP had to be entered as the log of the concentrations. The average (nmol/l)+ SEM of the ED50's was then calculated. The results are shown in Table 1. These give a quantitative idea of the shift, if any in the equilibrium binding curves .
  • the Scatchard plot of H-Ins demonstrates the characteristic curvilinear shape of negative co-operativity that should be exhibited by human insulin. It may be seen from the Scatchard plots of rT3-Ins and T4-Ins that these analogues also exhibit negative co-operativity due to their curvilinear shape.
  • T4 insulin is Bl-thyroxyl-insulin made according to the technique described in WO-A-95/05187 , Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On décrit un nouvel analogue de l'insuline dans lequel un 3,3',5'-tri-iodothyroxine est conjugué par covalence, de préférence au niveau du résidu B1. Le conjugué est estimé être hépatosélectif pendant qu'il conserve des propriétés de liaison au récepteur de l'insuline.
EP98928469A 1998-06-12 1998-06-12 Analogue de l'insuline Withdrawn EP1086130A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1998/001722 WO1999065941A1 (fr) 1998-06-12 1998-06-12 Analogue de l'insuline

Publications (1)

Publication Number Publication Date
EP1086130A1 true EP1086130A1 (fr) 2001-03-28

Family

ID=10825972

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98928469A Withdrawn EP1086130A1 (fr) 1998-06-12 1998-06-12 Analogue de l'insuline

Country Status (5)

Country Link
EP (1) EP1086130A1 (fr)
JP (1) JP2002518408A (fr)
AU (1) AU8029798A (fr)
CA (1) CA2334859A1 (fr)
WO (1) WO1999065941A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US20030186847A1 (en) * 2000-07-10 2003-10-02 Jones Richard Henry Insulin derivatives and synthesis thereof
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2004261319B2 (en) * 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
CN1964989B (zh) * 2003-07-25 2012-02-01 康久化学生物技术公司 长效胰岛素衍生物及其方法
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2008015099A2 (fr) 2006-07-31 2008-02-07 Novo Nordisk A/S Insulines pegylées à extensions
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2254905B1 (fr) 2008-03-14 2016-12-14 Novo Nordisk A/S Analogues de l insuline stabilisés une protéase
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
CA2870313A1 (fr) 2012-04-11 2013-10-17 Novo Nordisk A/S Formulations a base d'insuline
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
HUE060149T2 (hu) 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
DE69428134T2 (de) * 1993-09-17 2002-05-02 Novo Nordisk A/S, Bagsvaerd Acyliertes insulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9965941A1 *

Also Published As

Publication number Publication date
WO1999065941A1 (fr) 1999-12-23
JP2002518408A (ja) 2002-06-25
AU8029798A (en) 2000-01-05
CA2334859A1 (fr) 1999-12-23

Similar Documents

Publication Publication Date Title
EP1086130A1 (fr) Analogue de l'insuline
US8722849B2 (en) Polypeptides
RU2578591C2 (ru) Лекарственные средства, связанные с дипептидами
JP5977945B2 (ja) 長期のインビボ有効性を有するコンジュゲートタンパク質
EP2340261B1 (fr) Dérivés d'amyline
JP2848411B2 (ja) 心房性ナトリウム利尿ペプチドクリアランス阻害剤
CA2367856C (fr) Analogues de peptides d'inhibition gastrique et leur application au traitement du diabete
AU720966B2 (en) Insulin derivatives
US8114958B2 (en) Amylin family peptides
JP5969469B2 (ja) インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
JP2018123169A (ja) ヘプシジン類似体及びその使用
US20100144617A1 (en) Oxyntomodulin Derivatives
US20130137849A1 (en) Dipeptide linked medicinal agents
JP2000504732A (ja) インスリン誘導体類とその使用
KR20060096997A (ko) 신규 ｇｌｐ-1 유도체
JP2010116407A (ja) アシル化ｇｌｐ−１化合物
HUT69963A (en) Non-naturally-occuring fusion proteins and process for preparing them
JP2003535106A (ja) グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
JPH06228199A (ja) 血液脳関門通過可能なペプチド結合体
Hocart et al. Analogs of growth hormone-releasing factor (1-29) amide containing the reduced peptide bond isostere in the N-terminal region
WO2009156473A1 (fr) Peptides hybrides dérivés d’amyline et de calcitonine de saumon
US7015306B2 (en) Labeled neurotensin derivatives
US20030186847A1 (en) Insulin derivatives and synthesis thereof
JP2009502976A (ja) 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BTG INTERNATIONAL LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040415